Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

NSCLC is a less aggressive and more common form of lung cancer than SCLC. Your doctor will know which type of lung cancer you have when they take a biopsy, or small sample of the tumor, ...

When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies ...

The distant form, where SCLC has spread to a distant part of your body, is the most deadly. Its 5-year survival rate is only 3%. But nearly 70% of people with SCLC have this form when they’re ...

Serplulimab is the UK’s first licensed anti-PD-1 monoclonal antibody for this aggressive form of lung cancer. It is indicated for adults with untreated ES-SCLC, where the disease has spread ...

The SCLC was founded by Dr. Martin Luther King Jr., and others, to create a regional organization that could better coordinate civil rights protest activities across the south.

UK MHRA approves Accord Healthcare’s anti-PD-1 monoclonal antibody, serplulimab to treat aggressive form of SCLC: United Kingdom Monday, June 23, 2025, 09:00 Hrs [IST] The Medic ...